Reagents and instruments for immunology, cell biology and molecular biology.
 
> Recombinant Human TNF alpha Protein

Recombinant Human TNF alpha Protein

Print Print
Please log in

Cat# 230-00243-50

Size : 50ug

Brand : RayBiotech

Contact local distributor :


Phone : +1 850 650 7790

Recombinant Human TNF alpha ProteinRecombinant Human TNF alpha ProteinRecombinant Human TNF alpha ProteinRecombinant Human TNF alpha ProteinRecombinant Human TNF alpha Protein

Recombinant Human TNF alpha Protein

Recombinant Human TNF alpha Protein

Recombinant Human TNF-alpha
Contact Us for Bulk Request

Product Description

Specifications

Size10 µg, 50 µg, 100 µg
SpeciesHuman
Accession Number
P01375
Gene Id
7124
Gene Symbols
TNFA
Protein Name / Synonyms
TNFa, TNF-alpha, Tumor necrosis factor
Expressed Region
Val77-Leu233
Expression SystemE. coli
TagC-terminal 6x histidine tag
Purity
> 95%
Purity Determined BySDS-PAGE under reducing conditions and visualized by Coomassie blue staining
Molecular Weight (kDa)
17 kDa
Format
Liquid
Formulation
Supplied as a 0.2 µm filtered solution in PBS (pH 7.4)
Concentration (lot specific)
Lot specific (see the label on the vial)
Preservative
None
Endotoxin LevelNot determined
Research AreaCardiovascular Disease, Cancer, Inflammation, Antibody Drug Development, Drug Antibody (DA) Detection, Protein Therapeutics, Receptor-Ligand Binding
Shipping TypeBlue ice
Storage-20°C
SDS-PAGE Image
Activity
Measured by its binding ability in a functional ELISA. Immobilized recombinant TNFR1 can bind TNFa with EC50 at 3.82 ng/mL.
Storage/Stability
Upon arrival, the protein may be stored for two weeks at 2 to 8°C. For long term storage, it is recommended to add a carrier protein (0.1% HSA or BSA) and store at -20°C or -80°C in appropriate aliquots. Avoid repeated freeze-thaw cycles.

Data Images

Transcription factor activity assay of NF-κB p65 from nuclear extracts of HeLa cells or HeLa cells treated with TNF-α (RayBio Cat# 230-00243). After stimulation with TNF-α, activated NF-κB p65 is translocated into the nucleus where it binds with its corresponding DNA. A. Western blotting result of NF-κB p65 from cytoplasm and nuclear fractions; B. Transcription factor activity assay of NF-κB p65 from nuclear fractions, measured by TF-ELISA kit (RayBio Cat# TFEH-p65).

Figure 1

Transcription factor activity assay of NF-κB p65 from nuclear extracts of HeLa cells or HeLa cells treated with TNF-α (RayBio Cat# 230-00243). After stimulation with TNF-α, activated NF-κB p65 is translocated into the nucleus where it binds with its corresponding DNA. A. Western blotting result of NF-κB p65 from cytoplasm and nuclear fractions; B. Transcription factor activity assay of NF-κB p65 from nuclear fractions, measured by TF-ELISA kit (RayBio Cat# TFEH-p65).

Transcription factor activity assay of NF-κB p65 from nuclear extracts of HeLa cells or HeLa cells treated with TNF-α (RayBio Cat# 230-00243) with the specific competitor or non-specific competitor. The result shows specific binding of NF-κB p65 to the NF-κB DNA binding site.

Figure 2

Transcription factor activity assay of NF-κB p65 from nuclear extracts of HeLa cells or HeLa cells treated with TNF-α (RayBio Cat# 230-00243) with the specific competitor or non-specific competitor. The result shows specific binding of NF-κB p65 to the NF-κB DNA binding site.

Transcription factor activity assay of NF-κB p65 from nuclear extracts of HeLa cells treated with TNF-α (RayBio Cat# 230-00243) and purified NF-κB p50. No cross-reactivity has been observed between NF-κB p65 and p50.

Figure 3

Transcription factor activity assay of NF-κB p65 from nuclear extracts of HeLa cells treated with TNF-α (RayBio Cat# 230-00243) and purified NF-κB p50. No cross-reactivity has been observed between NF-κB p65 and p50.

citations

  • Neuroinflammation, autoinflammation, splenomegaly and anemia caused by bi-allelic mutations in IRAK4

    Year:
    2023
    Journal Name:
    Frontiers in immunology

  • Sanguinarine Inhibition of TNF-α-Induced CCL2, IKBKE/NF-κB/ERK1/2 Signaling Pathway, and Cell Migration in Human Triple-Negative Breast Cancer Cells

    Year:
    2022
    Journal Name:
    International Journal of Molecular Sciences

  • Diallyl disulfide inhibits TNF induced CCL2 release through MAPK/ERK and NF-Kappa-B signaling

    Species:
    Human
    Year:
    2015
    Journal Name:
    Cytokine
    PubMed ID:
    26100848

  • Attenuative Effect of Diallyl Trisulfide on Caspase Activity in TNF-α-induced Triple Negative Breast Cancer Cells

    Year:
    2023
    Journal Name:
    Anticancer Research

  • Diallyl Disulfide Inhibits TNF-induced CCL2 Release by MDA-MB-231 Cells

    Species:
    Human
    Sample Type:
    Conditioned Media (MDA-MB-231 Cells)
    Year:
    2014

  • Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum

    Species:
    Human
    Year:
    2012
    Journal Name:
    Journal of Immunological Methods
    PubMed ID:
    22691619